Ascendis Pharma Director Lars Holtug Files Form 144 for Tax-Related Share Sale
Ascendis Pharma A/S
Subscribe to track ASND
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Ascendis Pharma A/S ($ASND) – Form 144 Notice of Proposed Sale • Insider: Lars Holtug (Director) • Securities: Ordinary Shares • Shares to Sell: 236 (~$62.33K) • Approx. Date: 09/02/2026 • Broker: Citigroup Global Markets • Purpose: Sale of shares to cover income tax liabilities from compensation awards.
Comprehensive Analysis
Executive Summary
On September 2, 2026, Lars Holtug, a Director at Ascendis Pharma A/S ($ASND), filed a Form 144 notice covering the proposed sale of 236 Ordinary Shares with an aggregate market value of approximately $62,334.59 (indicative price of $264.13 per share). The sale is being executed via Citigroup Global Markets.
Transaction Details
- Security: Ordinary Shares
- Proposed Sale Units: 236
- Aggregate Market Value: $62,334.59
- Acquisition Source: Acquired via Share Plan Account as equity compensation on March 2, 2026.
- Transaction Purpose: Footnotes clarify this is a routine sale of shares to cover applicable income taxes.
Market & Governance Context
- Significance: Low.
- The volume of 236 shares is negligible relative to the issuer's 61,977,408 outstanding shares.
- Sell-to-cover transactions to satisfy tax obligations upon vesting or compensation distribution are standard corporate practices and do not represent a shift in insider sentiment regarding the company's fundamentals.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is AI-generated from public SEC filings and may contain errors. It is for informational and educational purposes only and is not investment, legal, or tax advice.
The Filing Fool is not a registered investment adviser, broker-dealer, or financial planner. Nothing here is a recommendation or solicitation to buy, sell, or hold any security.
Always do your own due diligence and consult a licensed professional.